Completed PHASE2 INTERVENTIONAL NCT00205478

Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo Controlled Study of Two Doses of VX-702 in Subjects With Moderate to Severe Rheumatoid Arthritis

Sponsor: Vertex Pharmaceuticals Incorporated

Conditions Rheumatoid Arthritis

Interventions VX-702

Updated 6 times since 2017 Last updated: Dec 5, 2007 Started: Jun 30, 2005 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00205478, this PHASE2 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Vertex Pharmaceuticals Incorporated, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vertex Pharmaceuticals Incorporated

Data source: Vertex Pharmaceuticals Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beograd, Serbia and Montenegro , Brno, Czechia , Bytom, Poland , Dniepropetrovsk, Ukraine , Donetsk, Ukraine , Elblag, Poland , Kiev, Ukraine , Krakow, Poland , Ljubljana, Slovenia , Lublin, Poland and 19 more locations